Physician profile
Dalia Frumkin
NPI 1164484135
$659.28
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $70.76 · 2023: $116 · 2024: $19.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $85.61 · Food and Beverage: $49.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $85.61 |
| Food and Beverage | $49.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $167.33 | 2019-2020 | |
| Vifor Pharma, INC. | $146.73 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $88.46 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $82.72 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $65.99 | 2023 | Acthar |
| Shield Therapeutics INC | $30.42 | 2023 | Accrufer |
| Fresenius USA Marketing, INC. | $22.01 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Heartflow, INC. | $19.44 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalia Frumkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.